Virios reports constructive FDA meeting for IMC-1 fibromyalgia; Long-COVID data expected June 2023

Dogwood Therapeutics, Inc.

End-of-Phase 2 FDA meeting for IMC-1 was constructive; Company seeks guidance to advance to Phase 3.
IMC-1 has been granted FDA Fast Track designation for fibromyalgia.
Topline results from IMC-2 Long-COVID trial (valacyclovir/celecoxib) expected in June 2023.
Company believes existing capital supports general and administrative operations into Q2 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.